Literature DB >> 10369849

Antibodies against human herpesvirus 8 in black South African patients with cancer.

F Sitas1, H Carrara, V Beral, R Newton, G Reeves, D Bull, U Jentsch, R Pacella-Norman, D Bourboulia, D Whitby, C Boshoff, R Weiss.   

Abstract

BACKGROUND: Infection with human herpesvirus 8 (HHV-8) has been consistently linked to Kaposi's sarcoma, but its mode of transmission, association with other cancers, and interaction with the human immunodeficiency virus type 1 (HIV-1) are largely unknown.
METHODS: Between January 1992 and December 1997, we interviewed 3591 black patients with cancer in Johannesburg and Soweto, South Africa. Blood was tested for antibodies against HIV-1 and HHV-8 in 3344 of the patients. Antibodies against HHV-8 were detected with an indirect immunofluorescence assay. The intensity of the fluorescent signal correlated well with the titers of antibodies (P<0.001). The relations among the presence of anti-HHV-8 antibodies, sociodemographic and behavioral factors, type of cancer, and the presence or absence of coexistent HIV infection were examined with the use of unconditional logistic-regression models.
RESULTS: Among the 3293 subjects with cancers other than Kaposi's sarcoma, the standardized seroprevalence of antibodies against HHV-8 was 32 percent, which did not differ significantly from the standardized seroprevalence among black blood donors. Among these 3293 patients, the prevalence of antibodies against HHV-8 increased with increasing age (P<0.001) and an increasing number of sexual partners (P=0.05) and decreased with increasing years of education (P=0.007); it was not strongly associated with HIV-1 infection. Anti-HHV-8 antibodies were more frequent among black than white blood donors (P<0.001). Among the 51 patients with Kaposi's sarcoma, the standardized seroprevalence of antibodies against HHV-8 was 83 percent, significantly higher than the prevalence among those without Kaposi's sarcoma (P<0.001). For 16 other specific types of cancer, including multiple myeloma (108 cases) and prostate cancer (202 cases), the variation in the standardized seroprevalence of antibodies against HHV-8 was not remarkable. At a given intensity of fluorescence of anti-HHV-8 antibodies, Kaposi's sarcoma was more frequent among HIV-1-positive patients than among those who were HIV-1-negative (P<0.001).
CONCLUSIONS: Among black patients with cancer in South Africa, the seroprevalence of anti-HHV-8 antibodies is high and is specifically associated with Kaposi's sarcoma, particularly at high titers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369849     DOI: 10.1056/NEJM199906173402403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  47 in total

1.  Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative population‐based sample in Uganda.

Authors:  Benon Biryahwaho; Sheila C Dollard; Ruth M Pfeiffer; Fatma M Shebl; Stella Munuo; Minal M Amin; Wolfgang Hladik; Ruth Parsons; Sam M Mbulaiteye
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

2.  HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data.

Authors:  Sam M Mbulaiteye; Kishor Bhatia; Clement Adebamowo; Annie J Sasco
Journal:  Infect Agent Cancer       Date:  2011-10-17       Impact factor: 2.965

Review 3.  Serodiagnosis for tumor viruses.

Authors:  Brian J Morrison; Nazzarena Labo; Wendell J Miley; Denise Whitby
Journal:  Semin Oncol       Date:  2014-12-31       Impact factor: 4.929

Review 4.  Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus.

Authors:  C Boshoff; R A Weiss
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

5.  Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells.

Authors:  M Mercader; B Taddeo; J R Panella; B Chandran; B J Nickoloff; K E Foreman
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

6.  Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions.

Authors:  Denise Whitby; Vickie A Marshall; Rachel K Bagni; Wendell J Miley; Thomas G McCloud; Rebecca Hines-Boykin; James J Goedert; Betty A Conde; Kunio Nagashima; Judy Mikovits; Dirk P Dittmer; David J Newman
Journal:  Int J Cancer       Date:  2007-01-15       Impact factor: 7.396

7.  Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma.

Authors:  R Tedeschi; M Enbom; E Bidoli; A Linde; P De Paoli; J Dillner
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

8.  Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults.

Authors:  Mhairi Maskew; A Patrick MacPhail; Denise Whitby; Matthias Egger; Matthew P Fox
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

9.  Lack of evidence for frequent heterosexual transmission of human herpesvirus 8 in Zimbabwe.

Authors:  Thomas B Campbell; Margaret Borok; Buxton Ndemera; Suzanne Fiorillo; Irene E White; Xing-quan Zhang; Rhoderick N Machekano; David Katzenstein; Lovemore Gwanzura
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

Review 10.  Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases.

Authors:  Dharam V Ablashi; Louise G Chatlynne; James E Whitman; Ethel Cesarman
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.